Topical anti-microbial peptide omiganan recovers cutaneous dysbiosis but does not improve clinical symptoms in patients with mild-to-moderate atopic dermatitis in a phase 2 randomized controlled trial N. der Kolk, T. P.Buters, L. Krouwels, J. Boltjes, M. L.de Kam, H. der Wall, D. C.J.G.van Alewijk, Ellen H.A.van den Munckhof, M. J.Becker, G. Feiss ,E. F.Florencia, P.Prens, M. MoerlandJ. Burggraaf, PhD1R. Rissmann, M. B.A. van DoornJournal of the American Academy of Dermatology, Available online 1 October 2020, In Press, Journal Pre-proof
Effects of lecithin-based nanoemulsions on skin: Short-time cytotoxicity MTT and BrdU studies, skin penetration of surfactants and additives and the delivery of curcumin Vatera, V. Hlawatya , P.Werdenitsa , M. A. Cichońc , V. Klanga, A. Elbe-Bürgerc , M. Wirtha , C. Valenta. International Journal of Pharmaceutics Volume 580, 30 April 2020, 119209
Skin tape proteomics identifies pathways associated with transepidermal water loss and allergen polysensitization in atopic dermatitis
E. Goleva, A. Calatroni, P. LeBeau, E. Berdyshev, P. Taylor, S. Kreimer, R. N. Cole, D. Y. M. Leung. Journal of Allergy and Clinical Immunology, published April 2020.
The effects of LXR agonist T0901317 and LXR antagonist GSK2033 on morphogenesis and lipid properties in full thickness skin models W.J. Heldera , W. A. Boitena , R. van Dijka , G. S. Goorisa , A. El Ghalbzourib , J. A. Bouwstra Biochimica et Biophysica Acta (BBA) – Molecular and Cell Biology of Lipids, Volume 1865, Issue 2, February 2020, 158546
Evolution of pathologic T-cell subsets in patients with atopic dermatitis from infancy to adulthood
T. Czarnowicki, H. He, T. Canter, J. Han, R. Lefferdink, T. Erickson, S. Rangel, N. Kameyama, H. Je Kim, A.B. Pavel, Y. Estrada, J.G. Krueger, A.S. Paller, E. Guttman-Yassky. The Journal of Allergy and Clinical Immunology, Atopic dermatitis and inflammatory skin disease, 145(1)215-228, January 2020.